Pharmacological targeting of type phosphodiesterase 4 inhibits the development of acute myeloid leukemia by impairing mitochondrial function through the Wnt/β-catenin pathway

Pharmacological targeting of type phosphodiesterase 4 inhibits the development of acute myeloid leukemia by impairing mitochondrial function through the Wnt/β-catenin pathway

Acute myeloid leukemia (AML) is prone to drug-resistant relapse with a low 5-year survival rate. New therapeutic modalities are sorely needed to provide hope for AML relapse patients. Herein, we demonstrated a specific inhibitor of type 4 phosphodiesterase (PDE4), Zl-n-91, could significantly reduce...

Full description

Bibliographic Details
Main Authors: Ping Mao, Changhao Huang, Yuyu Li, Yuanyi Zhao, Sujin Zhou, Zhenggang Zhao, Yunping Mu, Lina Wang, Fanghong Li, Allan Z. Zhao
Format: Article
Language:English
Published: Elsevier 2023-01-01
Series:Biomedicine & Pharmacotherapy
Subjects:
PDE4
Leukemia
AML
Mitochondria
WNT/β-catenin
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332222014160

Internet

http://www.sciencedirect.com/science/article/pii/S0753332222014160

Similar Items